References
- D'Ambrosio RD, Girzaitis N, Jusko WJ. Multicenter comparison of tacrolimus (FK 506) whole blood concentra-tions as measured by the Abbott Imx analyzer and enzyme immunoassay with methylene chloride extraction. Ther Drug Monit 1994; 16: 287–292.
- McCauley J, Van Thiel D, Jain A, Starzl TE. The effect of FK 506 upon renal function after liver transplantation. Transplant Proc 1990; 22: 17–20.
- Allessiani M, Cillo U, Fung J, et al. Adverse effects of FK 506 overdosage after liver transplantation. Transplant Proc 1990; 25: 628–634.
- Venkataramanan R, Jain A, Warty VS, et al. Pharmacokinetics of FK 506 in transplant patients. Transplant Proc 1991; 23: 2736-2740.
- Peters DH, Fitton A, Plosker GL, Faulds D. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993; 46: 746–794.
- Lee C, Jusko W, Shaefer M, et al. Pharmacokinetics of tacrolimus (FK 506) in liver transplant patients. Clin Pharmacol Ther 1993; 53: 181.
- Ihara H, Shinkuma D, Ichikawa Y, Nojima M, Nagano S, Ikoma F. Intra- and interindividual variation in the pharma-cokinetics of tacrolimus (FK 506) in kidney transplant recipi-ents—importance of trough level as a practical indicator. Int J Urol 1995; 2: 151–155.
- Aweeka FT, Tomlanovich SJ, Prueksaritanont T, Gupta SK, Benet LZ. Pharmacokinetics of orally and intravenously admnistered cyclosporine in pre-kidney transplant patients. J Clin Pharmacol 1994; 34: 60–67.